# Programme at a glance

**Tuesday 8 May: Pre-meeting training & development day (pg 14)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday 9</th>
<th>Thursday 10</th>
<th>Friday 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>0715</td>
<td>Registration opens</td>
<td>Hall 1: Opening &amp; Welcome</td>
<td>Registration opens</td>
</tr>
<tr>
<td>0745</td>
<td>Registration opens</td>
<td>Hall 1: Plenary session 1: Neuroinflammation</td>
<td>Special Interest Groups</td>
</tr>
<tr>
<td>0900</td>
<td>Hall 1: Opening &amp; Welcome</td>
<td>Hall 1: Plenary session 2: From genes to environment</td>
<td>Hall 1: Case presentation competition</td>
</tr>
<tr>
<td>0915</td>
<td>Hall 1: Plenary session 1: Neuroinflammation</td>
<td>Coffee, exhibition, silent symposia &amp; posters</td>
<td>Hall 1: Practical Neurology lecture</td>
</tr>
<tr>
<td>1030</td>
<td>Coffee, exhibition, silent symposia &amp; posters</td>
<td>Hall 3: Poster session with discussants 2</td>
<td>Coffee, exhibition, silent symposia &amp; posters</td>
</tr>
<tr>
<td>1115</td>
<td>Parallel sessions Hall 1: Signs &amp; symptoms</td>
<td>Hall 1: AGM, business session including models of acute neurology care</td>
<td>Hall 1: Plenary session 3: Acute neurology</td>
</tr>
<tr>
<td>1300</td>
<td>Lunch &amp; symposia Hall 9: Novartis Hall 11: Biogen</td>
<td>Lunch &amp; symposia Hall 9: Roche Hall 11: Teva</td>
<td>Hall 1: 6 top posters Hall 9: Merck</td>
</tr>
<tr>
<td>1315</td>
<td>Hall 1: Gordon Holmes lecture</td>
<td>Coffee, exhibition, silent symposia &amp; posters</td>
<td>Hall 1: Plenary session 4: Vascular neurology</td>
</tr>
<tr>
<td>1445</td>
<td>Hall 1: Video session</td>
<td>Parallel sessions Hall 1: Improving treatment Hall 9: MS &amp; other immune disorders</td>
<td>Hall 1: CPC</td>
</tr>
<tr>
<td>1545</td>
<td>MHRA</td>
<td>Hall 1: ABN Medallist lecture</td>
<td>Hall 1: Prize presentations and close</td>
</tr>
<tr>
<td>1600</td>
<td>Coffee, exhibition, silent symposia &amp; posters</td>
<td>Hall 1: ABN Medallist lecture</td>
<td>Hall 1: ABNT forum</td>
</tr>
<tr>
<td>1615</td>
<td>Parallel sessions Hall 1: Outcomes of neurological conditions Hall 9: Neurodegeneration</td>
<td>Hall 1: Making Headlines in Clinical Neuroscience</td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1630</td>
<td>Hall 1: Video session</td>
<td>Hall 1: ABN Medallist lecture</td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1645</td>
<td>Hall 1: Outcomes of neurological conditions Hall 9: Neurodegeneration</td>
<td>Hall 1: Making Headlines in Clinical Neuroscience</td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1715</td>
<td>Hall 1: Neurodegeneration</td>
<td>Hall 1: Making Headlines in Clinical Neuroscience</td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1730</td>
<td></td>
<td>Hall 1: Prize presentations and close</td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1745</td>
<td>Hall 3: Poster session with discussants 1</td>
<td></td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1750</td>
<td></td>
<td></td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1845</td>
<td>Hall 3: Drinks reception &amp; posters</td>
<td></td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1900</td>
<td></td>
<td></td>
<td>Gala dinner: Council House</td>
</tr>
<tr>
<td>1930</td>
<td>ABNT dinner: Bank</td>
<td></td>
<td>Gala dinner: Council House</td>
</tr>
</tbody>
</table>
**Tuesday 8**

**Pre-meeting training & development day**

| Time | **Room 8a:** I want to be a neurologist! A meeting for foundation doctors interested in neurology, *Chair: Chinar Osman* | **Room 8b:** Trainee session  
*Chairs: Sam Shribman & Angeliki Zarkali* |
|------|---------------------------------------------------------------|--------------------------------------------------|
| 1300 | What neurologists do and why:  
David Nicholl, Birmingham | Small group teaching: Referrals and triage - how to manage them: A&E, wards, ITU |
| 1330 | Who do neurologists work with?  
Relationships to neurophysiology, neurosurgery, neuropsychiatry, etc:  
Tom Warner, London | Alex Foulkes, London  
Tom Hayton, Birmingham  
Shanika Saramasekera, Birmingham  
Naz Sharaf, Manchester |
| 1350 | Case-based discussions 1 (acute neurology & stroke): Martin Punter, Manchester | 1445 Idiopathic intracranial hypertension: Alex Sinclair, Birmingham |
| 1435 | Case-based discussions 2 (neurology in clinic): Tabish Saifee, London | |
| 1515 | Hall 8 foyer: Coffee / tea break | |
| 1545 | Becoming a neurology trainee:  
Chinar Osman, Southampton | Neurocritical care: approaching the unconscious patient: Robin Howard, London |
| 1615 | **Room 8a:** Clinical skills laboratory - Keeping out of trouble: Adrian Williams, Birmingham | |
| 1700 | **Room 8 foyer:** Reception & light refreshments | |
| 1720 | **Room 8b:** Research session  
*Chair: Martin Turner*  
My working life - short talks with Q&A from consultants working with differing research tools  
Mary Reilly, London  
Jackie Palace, Oxford  
Kevin Talbot, Oxford  
Martin Turner, Oxford | |
| 1920 | Close | |
Wednesday 9

0745  Registration opens
0900  Hall 1: Opening and Welcome: President, President Elect
0915  Hall 1: Plenary session 1: Neuroinflammation
       Chairs: Alasdair Coles & Ben Turner
       CNS Vasculitis: Neil Scolding, Bristol
       What’s the next drug for MS?: Emma Tallantyre, Cardiff
       Neurological manifestations in Sjogren’s syndrome:
       Aleksandar Radunovic, London
1045  Coffee, exhibition, silent symposia & posters
1115  Parallel sessions

Hall 1: Signs & symptoms
       Chairs: David Nicholl & Nicola Giffin
1115  Apraxia and the temporal lobe in action: a role for biological motion:
       Elisabeth Rounis (pg 50)
1127  Novel genotype-phenotype and MRI findings in a large UK SPG7
       cohort: Channa Hewamadduma (pg 50)
1139  A screening questionnaire for transient loss of consciousness:
       Alistair Wardrope (pg 51)
1151  Skull base dural AVF mistaken as cervical myelitis: a series:
       Dan Whittam (pg 51)
1203  Cognitive and clinical features of rapid eye movement sleep
       behaviour disorder: Anna Nagy (pg 52)
1215  Understanding clinical variation in patients with single, large-scale
       mtDNA deletions: Hannah Hayhurst (pg 52)

Hall 9: Mechanisms of diseases
       Chairs: Trevor Pickersgill & Kirsty Harkness
1115  Predicting neurodegeneration after traumatic brain injury:
       Neil Graham (pg 53)
1127  Seizures, strokes and mitochondrial dysfunction: national cohort study:
       Yi Shiau Ng (pg 53)
1139  Immune-dysregulation in late onset myasthenia gravis: Girija Sadalage (pg 54)
1151  Alterations in regional cerebral blood flow during the premonitory
       phase of migraine: Nazia Karsan (pg 54)
1203  Quantifying muscle amyloid in inclusion body myositis using PET:
       James Lilleker (pg 55)
1215  Statins and the risk of intracerebral haemorrhage in stroke patients:
       Systematic review and meta-analysis: Oliver Ziff (pg 55)
Wednesday 9

1230 Lunch

1245 Hall 9: Novartis sponsored symposium
Combining ‘Magnetic’ Forces: Streamlining communication between neuro-radiologists and neurologists in MS (Details on pg 34)

1245 Hall 11: Biogen sponsored symposium
Early and accurate diagnosis of Alzheimers (Details on pg 35)

1400 Hall 1: Gordon Holmes lecture
Introduction: Kevin Talbot
Tau strains and spreading in pure tauopathy and Alzheimer’s disease: John Trojanowski, Pennsylvania

1445 Hall 1: Video session
Chairs: Martin Turner & Shanika Samarasekera
Sleep: Paul Reading, Middlesbrough
Epilepsy: Markus Reuber, Sheffield
Neuro-ophthalmology: Gordon Plant, London
Movement disorders: Chris Kobylecki, Manchester

1545 Sodium Valproate: MHRA update

1600 Coffee, exhibition, silent symposia & posters
1630 Parallel sessions - details on next page
1745 Hall 3: Poster session with discussants 1
1845 Hall 3: Drinks reception & posters
<table>
<thead>
<tr>
<th>Hall 1: Neurodegeneration</th>
<th>Hall 9: Outcomes of neurological conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairs:</strong> David Burn &amp; Oliver Bandmann</td>
<td><strong>Chairs:</strong> Chris Kipps &amp; Biba Stanton</td>
</tr>
<tr>
<td>1630 Neurofilament light protein as a biomarker for Huntington’s disease: Edward Wild (pg 56)</td>
<td>1630 Outcomes in low-grade glioma over 10 years: living longer and better: Jeremy Rees (pg 59)</td>
</tr>
<tr>
<td>1642 Using genetics to understand the molecular drivers of Huntington’s disease: Tom Massey (pg 56)</td>
<td>1642 Clinical outcome in MOG-antibody disease: a large single site cohort: Silvia Messina (pg 59)</td>
</tr>
<tr>
<td>1654: Longitudinal measurement of serum NfL in early familial AD: Philip Weston (pg 57)</td>
<td>1654 Multiple sclerosis outcomes 30-years after symptom onset: a longitudinal study: Karen Chung (pg 60)</td>
</tr>
<tr>
<td>1706: Genetic associations of ICD in Parkinson’s disease: Richard Rees (pg 57)</td>
<td>1706 Autoantibody production following traumatic brain injury is associated with poor outcome: Edward Needham (pg 60)</td>
</tr>
<tr>
<td>1718 Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy: Thomas Cope (pg 58)</td>
<td>1718 Predictors of dyskinesia in early Parkinson’s: results from the Oxford discovery cohort: Mark Kelly (pg 61)</td>
</tr>
<tr>
<td>1730 Abnormal growth hormone response to Clonidine: early biomarker in Multiple System Atrophy: Valeria Iodice (pg 58)</td>
<td>1730 Predicting post stroke cognitive trajectory Rosanna Laverick (pg 61)</td>
</tr>
</tbody>
</table>
Thursday 10

0715  Registration open
0745  Special Interest Groups

Media Suite: **Cognitive disorders**  
*Chair: Paresh Malhotra*  
Case Presentations from the Cognitive Disorders Clinic  
Speakers: Maz Matar, Dan Blackburn & Akram Hosseini

Hall 9: **Movement disorders**  
*Chair: Carl Clarke*  
Educational movement disorders videos for generalists  
Co-presenters include: David Nicholl & Ben Wright

Hall 1: **Neuro-ophthalmology**  
*Chair: Gordon Plant*  
Interactive case presentations

Hall 11: **Peripheral nerve**  
*Chair: Haider Katifi, co-chair: Yusuf Rajabally*  
Peripheral neuropathy case study – approach to diagnosis and management

0900  Hall 1: Plenary session 2: From genes to environment  
*Chairs: Lina Nashef & Ralph Gregory*  
Antisense oligonucleotide therapy for Huntington’s disease – results from the first HTT lowering clinical trial: Sarah Tabrizi, London  
Nutritional deficiencies - from famine to feast: Lionel Ginsberg, London  
Advances in neurology through adversity - warfare: Matthew Craner, Oxford

1030  Hall 3: Coffee, exhibition, silent symposia & posters
1100  Hall 3: Poster session with discussants 2
1145  Hall 1: AGM  
*Chair: Mary Reilly*  
Business session  
*Chair: Cath Mummery*  
Geraint Fuller: Clinical lead for Neurology, Getting It Right First Time  
Adrian Williams: Chair, National Neurosciences Advisory Group

Models of acute neurology care delivery  
Transforming acute neurology care: a four year study: Arani Nitkunan  
Acute neurology in Aneurin Bevan University Health Board: Joe Anderson  
Piloting and implementing an acute neurology service: Thomas Peukert  
Hyperacute stroke unit and hyperacute neurology unit under one roof: Joyutpal Das

1315  Lunch

1330  Hall 9: Roche sponsored symposium  
MS: Beyond the Relapse (Details on pg 36)

1330  Hall 11: Teva sponsored symposium  
Entering a new era for migraine management (Details on pg 37)
1445  Parallel sessions
<table>
<thead>
<tr>
<th>Hall 1: Improving treatment</th>
<th>Hall 9: MS &amp; other immune disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Chairs: Lucy Kinton &amp; Stephan Hinze</em></td>
<td><em>Chairs: Jacqueline Palace &amp; Saiju Jacob</em></td>
</tr>
<tr>
<td>1445 Optimising outpatient management of epilepsy patients in the tertiary care setting: Dipa Raja Rayan (pg 64)</td>
<td>1445 Challenges in reducing hospital deaths in multiple sclerosis: Richard Nicholas (pg 67)</td>
</tr>
<tr>
<td>1457 A new UK reproductive care pathway for women with serious mtDNA disease: Grainne Gorman (pg 64)</td>
<td>1457 MRI abnormalities in MOG antibody disease: Saif Huda (pg 67)</td>
</tr>
<tr>
<td>1509 CSF chitinases as novel biomarkers for MND: Alexander Thompson (pg 65)</td>
<td>1509 Nimodipine alleviates relapse &amp; prevents demyelination in MS models: Kenneth Smith (pg 68)</td>
</tr>
<tr>
<td>1521 Effect of idebenone on bronchopulmonary adverse events and hospitalizations in patients with Duchene muscular dystrophy (DMD): Catherine Lawrence (pg 65)</td>
<td>1521 Novel HLA association of CASPR2 antibody mediated neurological disease: James Varley (pg 68)</td>
</tr>
<tr>
<td>1533 St George’s hyperacute neurology: right person, right time: Kuven Moodley (pg 66)</td>
<td>1533 Neurosarcoidosis – review of 91 patients from three UK neuroscience centres: Reem Farwana (pg 69)</td>
</tr>
<tr>
<td>1545 Mapping patient pathways for acute functional neurological symptoms: Stefan Williams (pg 66)</td>
<td>1545 Autoimmune autonomic ganglionopathy: the NHNN experience: Junie Shiwen Koay (pg 69)</td>
</tr>
</tbody>
</table>

**Thursday 10**

**1600** Hall 3: Coffee, exhibition, silent symposia & posters

**1630** Hall 1: ABN Medallist lecture  
*Chair: Mary Reilly*  
From frogs to man: the eyes have it: Chris Kennard, Oxford  
Citation: Raad Shakir, London

**1715** Making Headlines in Clinical Neuroscience  
*Chairs: Mary Reilly & Simon Rinaldi*  
Microglia-mediated recovery in a mouse model of ALS: Virginia Man-Yee Lee, Pennsylvania  
Late Breaking news: see Stop Press bookmark for details

**1750** Hall 1: ABNT forum

**1900** Drinks reception: Birmingham Museum & Art Gallery, followed by  
**2000** Gala Dinner: Banqueting suite at Council House  
Please enquire at registration desk for availability
0700  Registration opens

0745  Special Interest Groups

Media Suite: British Myology Society
Muscle disease practical clinical update on behalf of British Myology Society
-all consultants and trainees welcome
- Common muscle conditions - clinical-genetic diagnosis and management: Michael Hanna
- Case presentation - ‘WODs the matter’: Simon Hammans
- Discussion and Q and A

Hall 11: Functional disorders
0745 Welcome: Markus Reuber
0750 Physiotherapy for functional motor symptoms: outcomes from a randomised feasibility study and plans for a multicentre RCT: Glenn Nielsen, St George’s Hospital, London
0815 Questions and discussion
0825 Interactive video session: diagnostic challenges in functional neurology. Range of speakers including Chrissie Burness & Markus Reuber
0845 Close

Hall 1: MS & neuroinflammation
Chairs: Neil Robertson & Victoria Williams
0745 A case of Tumefactive MS: Sonia Kumari
0800 Early aggressive and escalation treatment paradigms in MS: a comparative analysis: Katharine Harding
0815 Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients: Daniel Whittam
0830 Work of the ABN MS and Neuroinflammation Advisory Group; 2017-18 review: Alasdair Coles
0845 Close

0900  Hall 1: Case presentation competition

If you would prefer not to know the diagnoses, please do not read the abstracts for these cases.

Chair: Phil Smith
0900  A new face for an old foe?: Gavinda Sangha (pg 70)
0912  When the microbiologist can’t help: Angeliki Zarkali (pg 70)
0924  Disentangling corticobasal syndrome from corticobasal degeneration: Ruth Lamb (pg 71)
0936  Thinking about ‘Plan B’: Stephen Keddie (pg 71)
0948  It’s an unfair cop: Vamsi Chinthapalli (pg 72)
1000  Inspector NORSE: Amy Ross Russell (pg 72)
1015  Hall 1: Practical Neurology lecture
*Introduction: Geraint Fuller & Phil Smith*
Bringing neurology care back home: Bastiaan Bloem, Nijmegen NL

**1100 Hall 3: Coffee, exhibition, silent symposia & posters**

1130  Hall 1: Plenary session 3: Acute neurology
*Chairs: Derek Bell & Richard Davenport*
Neurology of obstetrics: Dominic Heaney, London
Neurological consults on the ITU: Max Damian, Cambridge
Acute medicine and the importance of the specialty interface: Derek Bell, RCPE

**1300 Lunch**

1315  Hall 1: 6 top posters
Discussant: Tom Warner

1315  Hall 11: Merck sponsored symposium
DMT Sequencing algorithms in MS: How does MAVENCLAD (cladribine 10mg tablets) contribute? (Details on pg 38)

1430  Hall 1: Plenary session 4: Vascular neurology
*Chairs: David Werring & Joanna Lovett*
What’s new in preventing stroke - personalising treatment for different types of stroke: Hugh Markus, Cambridge
Stroke in the young: Tom Hughes, Cardiff
Stroke thrombectomy - challenges for service implementation: Jeremy Madigan, London

1600  Hall 1: Clinicopathological Conference
*Chair: Jon Sussman*
Discussant: David McKee

1645  Hall 1: Prize presentations and close